Patent Issued on Fusion-Protein Vaccine

New Post Public Reply Private Reply Replies (0) Message Board
Roger Wilco

Patent Issued on Fusion-Protein Vaccine Technology

Date : 02/29/2012 @ 7:30AM
Source : PR Newswire
Stock : Ibio Common Stock (IBIO)
Quote : 0.806  0.0 (0.00%) @ 8:33AM

Patent Issued on Fusion-Protein Vaccine Technology

Ibio Common Stock (AMEX:IBIO)
Intraday Stock Chart

Today : Wednesday 29 February 2012

Click Here for more Ibio Common Stock Charts.

iBio, Inc. (NYSE AMEX: IBIO) today announced issuance of a US patent covering the use of iBio's proprietary fusion-protein technology in combination with influenza virus antigens for vaccine product applications. The invention comprises the use of lichenase in an adjuvant-like role to improve the performance of vaccines. This approach was developed by the Fraunhofer USA Center for Molecular Biotechnology (FhCMB), iBio's research collaborator. The new patent is US Patent 8,124,103, entitled "Influenza Antigen, Vaccine Compositions, and Related Methods".

The vaccine industry is increasingly focused on the development of subunit vaccines. These subunit vaccines require use of components called adjuvants for improving their efficacy. Lichenase, when fused to antigens acts as an adjuvant and can improve the efficacy of vaccines.  Fusion of lichenase to vaccine antigens can enhance duration of immune response, improve production economies and increase product stability.  This approach could provide significant advantages over more conventional methodologies used to improve vaccine efficacy.

"We consider the issuance of this patent to be an important step in the expansion of opportunities in subunit vaccine development," said Vidadi Yusibov, Ph.D., one of the patent's inventors and Executive Director of FhCMB. "We previously published data demonstrating significant improvement in candidate vaccine performance in animal models when lichenase technology is employed with a range of target antigens, including antigens from plague, malaria, and human papilloma virus."

"While iBio's principal focus has been to optimize and commercialize our proprietary platform technology for broad commercial applications across the biologics field, we also have been bringing forward lichenase as a separate proprietary product platform to be licensed to enhance vaccine performance," said Robert B. Kay , Executive Chairman and CEO of iBio.  "Based upon the results obtained in multiple animal studies and the formulation advantages of using a fusion protein, we believe there will be substantial commercial interest in lichenase as a proprietary approach for potent subunit vaccines."

This patent is an important addition to iBio's broader intellectual property portfolio that includes the clinical-stage iBioLaunch™ platform for vaccines and therapeutic products. 

About iBio, Inc.

iBio develops and offers product applications of its iBioLaunch™ platform, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of vaccines and therapeutic proteins using transient gene expression in green plants. The technology has been applied successfully to proteins difficult or impossible to produce with other methods, as well as proteins representative most important classes of biologic pharmaceuticals. Advantages of the iBioLaunch platform over other systems include enablement of rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more; product entry that is unconstrained by traditional process patents; and significantly lower capital and operating costs for comparable production. Further information is available at: www.ibioinc.com .

About Fraunhofer USA Center for Molecular Biotechnology

Fraunhofer USA CMB, a division of Fraunhofer USA , Inc., is a not-for-profit research organization whose mission is to develop safe and effective vaccines targeting infectious diseases and autoimmune disorders. The Center conducts research in the area of plant biotechnology, utilizing new, cutting edge technologies to assist with the diagnosis, prevention and treatment of human and animal diseases. The Center houses individuals with expertise and excellence in plant virology, pathology, molecular biology, immunology, vaccinology, protein engineering, and biochemistry. Further information is available at www.fraunhofer-cmb.org .

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Job Market Shifts: Adaptation vs. Fairness Dilemma

Updated Category News Views 2

The Chameleon Effect in Today's Job Market Walk into any open-space office these days, and you'll see faces plastered with composed, work-ready smiles—faces that might not look so familiar outside those walls. The modern workplace has draped its cloak over individual personalities, with the mighty pressure to 'fit in' often forcing a change in how folks present...

Continue Reading
MCatalysis Secures $5M to Disrupt Fuel Cost Dynamics

Updated Category News Views 3

Funding Fuels Innovation MCatalysis has just secured a hefty $5 million in seed funding to throw down with the big dogs in energy production. This isn't your regular backyard science project; this company is serious about changing the game with a tech-driven approach that could undercut current fuel prices. HL Energy Ventures and Oxford Science Enterprises are backing...

Continue Reading
LeoLabs and SciTec Partner for $93.7M Space Force Deal

Updated Category News Views 1

LeoLabs and SciTec Join Forces for Space Dominance The space race ain't just about rockets blasting off anymore. It's about making sure we've got eyes everywhere, even on the back of our heads, so to speak. Enter LeoLabs teaming up with SciTec to help the U.S. Space Force upgrade their radar systems to something out of a sci-fi flick, armed with a $93.7 million contract...

Continue Reading
Cap Juluca: Caribbean Luxury Redefined on Maundays Bay

Updated Category News Views 0

The Tranquil Call of Maundays Bay Find me dipping my toes in the sands of Maundays Bay come October 10, 2026, and you'll understand why this slice of Anguilla stakes its claim to being the best beach on the globe. Cap Juluca, that crown jewel of Caribbean luxury, swings open its doors once more, promising indulgence framed by turquoise waters and the soft whisper of white...

Continue Reading
EFSI Shareholders on Alert Amid M&A Deal Scrutiny

Updated Category News Views 1

Eagle Financial Services Under the Microscope A buzz is picking up in the world of mergers and acquisitions, and this time, it's Eagle Financial Services, Inc. (NASDAQ: EFSI) caught in the crosshairs. What's the chatter all about? Well, it looks like Juan Monteverde and his crew over at Monteverde & Associates PC have set their sights on Eagle's proposed sale to John...

Continue Reading
CUBEX Lights Up Veterinary Care with Mini Essential

Updated Category News Views 5

Inventory Woes? Meet Mini Essential If you’ve ever worked in or around veterinary hospitals, you know the old-school headaches of managing controlled substances. Picture this: piles of paper logs, end-of-shift recounting, and inevitable discrepancies that rear their ugly heads long after closing time. Enter CUBEX, shaking things up with their latest launch, Mini...

Continue Reading
Midlife ADHD in Women: New Challenges and Solutions

Updated Category News Views 1

ADHD Evolution in Women's Midlife They say change is the only constant, and boy, does that ring true for women navigating the turbulent seas of ADHD as they hit 40 and beyond. According to Germaine Swanson, the ADHD landscape changes dramatically in midlife, especially for women. We're talking about a mix of hormonal shifts, increasing life demands, and changes in brain...

Continue Reading
Global Communication Works Opens SignlLabs™ AI Licensing

Updated Category News Views 29

AI Signaling Moves Beyond GCW's Own Clients Remember when we first looked at GCW's SignlLabs and the idea of helping brands show up inside ChatGPT, Gemini, Claude, Copilot and Perplexity? Well, Global Communication Works is taking the next step. Instead of keeping its AI Signaling playbook inside the agency walls, GCW is now opening SignlLabs up for licensing

Continue Reading
RARE Foundation Rebrands, Focus Still Strong

Updated Category News Views 1

Unveiling the RARE Foundation's New Identity In the stock market, you ride waves of change, and let me tell you, it ain't just stocks and bonds that change names and faces. Case in point: The EveryLife Foundation for Rare Diseases has spiffed up as the RARE Foundation. New name, new logo, the whole enchilada. This isn't just a cosmetic touch-up, though. It's about...

Continue Reading
Sacrifice Unending: 9/11's Lingering Health Toll

Updated Category News Views 0

The Unseen Toll of 9/11 on the Firefighter Community Two and a half decades since that fateful morning of September 11, 2001, we're staring at a grim reality. The heroic souls of the New York City Fire Department (FDNY)—those who ran toward peril when others ran away—are still paying the price. Incredibly, more than 400 FDNY members have succumbed to World Trade...

Continue Reading

Top 5 Most Recently Viewed Articles

Indian Podcast Market Expected to Surge to $4.25 Billion

Updated Category News Views 1388

Significant Growth Ahead for the Indian Podcast Market The Indian podcast market is experiencing remarkable growth, valued at US$ 560 million in the previous year, with expectations to reach a staggering US$ 4,248 million by the year 2033. This impressive growth is projected at a CAGR of 25.5% over the forecast period. As the digital landscape evolves, podcasts are...

Continue Reading
Investor Alert: Designer Brands Inc. Faces Securities Investigation

Updated Category News Views 171

Investigation of Designer Brands Inc. Securities Rosen Law Firm, known for advocating for investor rights, is currently investigating potential securities claims on behalf of shareholders of Designer Brands Inc. (NYSE: DBI). The investigation is prompted by allegations that Designer Brands may have provided materially misleading information to its investors, which could...

Continue Reading
Significant Upsurge in Meme Coins and Innovative Projects

Updated Category News Views 137

Creating Opportunities in the Cryptocurrency Ecosystem In an exhilarating development for the cryptocurrency market, Bitcoin has recently surged to remarkable heights, exceeding the $110,000 mark. This surge has ignited a wave of positivity across the space, and leading global cryptocurrency exchange HTX is excited to share insights from its fifth installment of the...

Continue Reading
GreetEat Corp. Unveils Ambitious Plan for Future Growth

Updated Category News Views 140

GreetEat Corp. Charts Ambitious Path Forward GreetEat Corp. (OTC: GEAT), known for its innovative virtual dining and delivery platform, is setting the stage for significant expansion and growth. Recently, CEO Vishal Patel shared a compelling letter with shareholders, shedding light on the company’s strategic vision for the upcoming years. The landscape of dining and...

Continue Reading
Nordstrom Celebrates Continued Commitment with Dividend Approval

Updated Category News Views 175

Nordstrom's Board of Directors Approves Quarterly Dividend Today, Nordstrom, Inc. (NYSE: JWN) confidently announced that its board of directors has approved a quarterly dividend, reflecting the company's unwavering commitment to returning value to its shareholders. Nordstrom has set the dividend at 19 cents per share, which will be paid out to shareholders who are on...

Continue Reading